BTAI · BioXcel Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Feb 10, 2025; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BTAI
this stock
BioXcel Therapeutics, Inc.
|
$3.35M | -95.4% | -71.7% | — | 10.6% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$59.75B | +18.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$47.50B | -5.8% | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.83B | -5.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Feb 10, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BTAI | -59.2% | -91.8% | -95.2% | -54.7% | -95.4% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -59.3% | -91.4% | -110.3% | -55.1% | -108.3% |